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Abstract
Background: Parathyroid adenomas constitute the most common entity in primary hyperparathyroidism, and although
recent advances have been made regarding the underlying genetic cause of these lesions, very little data on epigenetic
alterations in this tumour type exists. In this study, we have determined the levels of promoter methylation regarding the
four tumour suppressor genes APC, RASSF1A, p16
INK4A and RAR-b in parathyroid adenomas. In addition, the levels of global
methylation were assessed by analyzing LINE-1 repeats.
Methodology/Principal Findings: The sample collection consisted of 55 parathyroid tumours with known HRPT2 and/or
MEN1 genotypes. Using Pyrosequencing analysis, we demonstrate APC promoter 1A and RASSF1A promoter
hypermethylation in the majority of parathyroid tumours (71% and 98%, respectively). Using TaqMan qRT-PCR, all tumours
analyzed displayed lower RASSF1A mRNA expression and higher levels of total APC mRNA than normal parathyroid, the
latter of which was largely conferred by augmented APC 1B transcription levels. Hypermethylation of p16
INK4A was
demonstrated in a single adenoma, whereas RAR-b hypermethylation was not observed in any sample. Moreover, based on
LINE-1 analyses, parathyroid tumours exhibited global methylation levels within the range of non-neoplastic parathyroid
tissues.
Conclusions/Significance: The results demonstrate that APC and RASSF1A promoter hypermethylation are common events
in parathyroid tumours. While RASSF1A mRNA levels were found downregulated in all tumours investigated, APC gene
expression was retained through APC 1B mRNA levels. These findings suggest the involvement of the Ras signaling pathway
in parathyroid tumorigenesis. Additionally, in contrast to most other human cancers, parathyroid tumours were not
characterized by global hypomethylation, as parathyroid tumours exhibited LINE-1 methylation levels similar to that of
normal parathyroid tissues.
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Introduction
Primary hyperparathyroidism (PHPT) is a common endocrine
disorder which denotes the tumorous enlargement of one or more
of the parathyroid glands. While the genetic background of PHPT
has been partly elucidated, the involvement of epigenetic
modifications remains unresolved. Mutations in the HRPT2 (also
known as CDC73) and MEN1 tumour suppressor genes are two
important genetic events propelling parathyroid tumorigenesis
[1–3]. The protein product of HRPT2 is parafibromin, which is
functionally linked to the canonical part of the Wingless type (Wnt)
pathway [4]. Parafibromin is a part of the human polymerase
associated factor complex (hPAF) which is required for facilitating
transcription elongation and histone modifications [5–6]. Further-
more, parafibromin has been shown to associate with the Wnt
oncoprotein b-catenin and to down-regulate c-Myc oncogene
transcription through direct binding to the c-Myc promoter
region, supporting the role of parafibromin as a tumor suppressor
protein that inhibits Wnt signaling [7]. Interestingly, the MEN1
product menin was also coupled to the Wnt pathway, demon-
strated by its epigenetic regulation of Axin2 and by expression
profiling of MEN1 knock-out mice [8–9].
To broaden the knowledge of epigenetic events in parathyroid
tumour development, we sought to determine the levels of
promoter methylation of four tumour suppressor genes; APC
(adenomatous polyposis coli), p16
INK4A, RASSF1A (Ras association
domain family protein 1) and RAR-b (Retinoic acid receptor-beta),
all known to be widely hypermethylated in various human cancers
as well as exhibiting potential as parathyroid tumour suppressor
genes. APC mutations are responsible for the autosomal dominant
familial adenomatous polyposis (FAP) syndrome [10–11], and are
also found in sporadic colorectal cancer as well as in other tumour
types, such as cancer of the thyroid and mammary glands [12–13].
Hypermethylation of the APC promoter 1A has been demonstrat-
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Furthermore, loss of APC immunoreactivity has recently been
implicated in parathyroid malignant tumours [16]. The tumour
suppressor protein p16
ink4A regulates the G1 to S phase transition
of the cell cycle through its inhibition of the interaction between
Cdk 4/6 and cyclin D1. Parathyroid tumours often demonstrate
over-expression of cyclin D1, thus making the p16
ink4A gene an
interesting candidate for promoter methylation assays since
p16
ink4A inactivation might produce parallel oncogenic effects
analogous to cyclin D1 up-regulation [17]. p16
ink4A gene mutations
have been sought in parathyroid tumours due to the presence of
9p21-pter deletions in small subsets of parathyroid adenomas;
however, no mutations have been demonstrated [18].
The RASSF1A gene localized to 3p21 is epigenetically
inactivated with high regularity in human cancers as well as in
endocrine tumours such as pheochromocytomas and follicular
thyroid cancer [19–21]. Interestingly, RASSF1A has been shown
to down-regulate cyclin D1 expression in addition to its role as a
Ras-binding protein, hypothetically making the RASSF1A gene a
potential candidate as a parathyroid tumour suppressor gene [22].
RAR-b is a member of the nuclear receptor superfamily with the
main function to convey retinoid signaling into target gene
transcription in the nucleus. The RAR-b promoter exhibit frequent
hypermethylation in various tumours, as for instance in breast-
and prostate cancer as well as in malignant mesothelioma [23–25].
Recently, it was shown that up-regulation of the oncogene c-myc
increased the levels of RAR-b promoter methylation in a prostate
cell line, suggesting that these events might be directly or indirectly
coupled [26]. These finding are of particular interest as c-myc
over-expression has been demonstrated in parathyroid tumours
[27].
In addition to gene-specific hypermethylation, global hypo-
methylation is a common characteristic in human cancers
[28–29]. LINE-1 (long interspersed nuclear elements-1) retro-
transposons denote replicating repetitive elements which constitute
about 15% of the human genome. CpG sites within the LINE-1
promoter region are normally heavily methylated to protect from
retrotransposon activation, and LINE-1 hypomethylation is a
noted epigenetic event in human tumourigenesis. For example,
LINE-1 promoter hypomethylation is common in colon cancer,
and the retrotransposal insertion of a LINE-1 sequence has been
directly shown to disrupt the APC gene in a case of colon cancer
[29–30]. Furthermore, quantifying LINE-1 promoter methylation
densities have been shown to be a reliable substitute for global
methylation assays [31].
Towards these ends, we have quantified promoter methylation
of APC, RASSF1A, p16
INK4A, RAR-b and LINE-1 repeats in a series
of parathyroid tumours characterized for HRPT2 and MEN1
genotypes.
Results
The APC and RASSF1A Promoters Are Hypermethylated
in Parathyroid Tumours
In total, 55 parathyroid tumors were assessed for APC,
RASSF1A, p16
INK4A and RAR-b regional promoter methylation
using Pyrosequencing analysis. Examples of Pyrograms are
illustrated in Figure 1 and the results are summarized in Table 1.
The density of promoter methylation in each tumour was
calculated as a mean for the individual CpG residues, and the
results are also presented as the range from minimum to
maximum methylation density for the individual sites assessed
(Table 1). The results indicate that CpG-specific methylation in
parathyroid tumours is a common event at the APC and RASSF1A
promoters but rarely occur at the p16
INK4A and RAR-b promoter
loci (Figure 2). For APC, the mean CpG methylation ranged from
1.5% (case RAD1) to 77.5% (case H2) in our panel (Table 1).
Normal parathyroid tissues (Normal PT 1–3) displayed very low
levels of APC promoter methylation (2.2%, 4.0% and 3.3%;
Table 1). In addition, SHPT1, thymus tissue from case H1 as well
as leukocyte DNA from patient RAD2 also exhibited low APC
methylation (2.3% and 2.5%), in agreement with previous report
of low APC methylation density in other non-neoplastic tissues
such as colonic mucosa (#5%) [32]. In our study, a total of 39 out
of 55 tumours (71%) were considered to exhibit a hypermethylated
APC promoter 1A (above 10% density) as compared to the 16
tumours (29%) with very low methylation (below 10% density).
Twenty-four out of the 34 cystic parathyroid adenomas (71%)
exhibited hypermethylation, as well as 14 out of 19 (74%) of the
regular parathyroid adenomas. For the two cases with germ-line
HRPT2 gene mutations (H1-2), the atypical adenoma case H1
presented with virtually no methylation (2.3%), whereas the
parathyroid adenoma H2 was endowed with the highest density of
APC methylation in the entire series (77.5%).
For RASSF1A, the methylation ranged from 8% (CAD13) to 80%
(RAD4) and 54 out of 55 (98%) tumours displayed methylation
densities above 10% (Table 1, Figure 2). The three normal
parathyroid samples presented with almost no RASSF1A promoter
methylation and additional non-tumorous controls consisting of
normal thymus and leukocyte DNA also displayed low levels of
RASSF1A methylation. Case SHPT1 however exhibited an average
methylation density of 30.2% (Table 1, Figure 2). There was a
significant but weak positive correlation between APC and RASSF1A
methylation levels, suggesting that tumours with high levels of APC
methylation density frequently demonstrate high RASSF1A meth-
ylation levels (Pearson’s correlation 0.301, p=0.022, Table 2).
Regarding p16
INK4A promoter methylation, one case was found
to be hypermethylated as compared to non-tumorous controls
(RAD2, 14.9%). The remaining 54 cases (98%) displayed very low
mean levels of promoter methylation densities (,10%) (Table 1).
However, nine of these cases were found to exhibit methylation
levels above 10% at one or more individual CpG sites, with
preferentially involvement of CpG site 7. For RAR-b, all tumours
and normal controls displayed low levels of promoter methylation
(,10%) (Table 1).
Assessment of Global Methylation in Parathyroid
Tumours
Regarding LINE-1 promoter methylation, normal parathyroid
tissues ranged from 59.7% to 72.3%, thereby encompassing
the vast majority (45/55; 82%) of all parathyroid tumours
investigated.
Comparison of Promoter Methylation Density with
Clinical and Genetic Parameters
Possible correlations were evaluated between methylation
density of the individual hypermethylated APC and RASSF1A
promoters with clinical and genetic characteristics (Table 1,
Table 2, Table 3 and Table S1). No significant correlations were
observed between APC promoter hypermethylation and serum
levels of calcium, PTH or glandular weight (Table 2). For
RASSF1A, no correlation between methylation levels and serum
calcium, PTH or glandular weight was demonstrated; however,
increased levels of RASSF1A methylation correlated negatively
with serum calcium (Table 2).
All MEN1 mutated tumours in the current study displayed APC
promoter 1A hypermethylation, and a weak but significant
Promoter Methylation in PHPT
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9472Figure 1. Examples of Pyrograms for quantification of methylation densities. 10 CpG sites of the APC promoter 1A, 5 CpG sites of the
RASSF1A promoter and 7 CpG sites of the p16
INK4A promoter are shown for case RAD 13, a tumour carrying a somatic MEN1 mutation. The tumour
displays methylation densities of 33.9% at APC (range 16–41%), 58.2% at RASSF1A (range 49–68%) and 1.6% at p16
INK4A (range 1–3%), respectively.
Nucleotides at position #16 of the APC promoter region 1A and at position #32 of the p16
INK4A promoter (yellow) are examples of CpG free cytosine
residues which serve as internal controls for satisfactory bisulphite-driven C to T conversion for each DNA sample.
doi:10.1371/journal.pone.0009472.g001
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PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9472Table 1. Results from the gene promoter methylation analyses in parathyroid tumours and control tissues.
Case
APC
methylation {
RASSF1A
methylation {
p16
INK4A
methylation {
RAR-b
methylation {
LINE-1
methylation { Genotypes*
no. mean % (range) % mean % (range) % mean % (range) % mean % (range) % mean % (range) % MEN1 HRPT2
Tumour samples
CAD1 2.7 (2–5) 39.6 (24–55) 8.1 (2–27) 1.0 (1–1) 66.3 (64–69) wt wt
CAD2 2.7 (2–4) 45.2 (34–59) 1.3 (1–2) 0.9 (0–2) 67.3 (66–70) wt wt
CAD3 2.9 (2–4) 46.8 (28–64) 2.1 (1–5) 1.1 (1–2) 67.0 (65–69) wt wt
CAD4 3.4 (2–4) 37.2 (22–48) 2.9 (1–5) 0.9 (0–1) 68.3 (65–71) wt wt
CAD5 3.6 (2–6) 50.0 (35–71) 4.4 (2–14) 1.0 (0–2) 67.7 (64–70) wt wt
CAD6 3.8 (3–5) 40.6 (27–57) 1.4 (1–2) 1.9 (1–3) 72.3 (70–75) wt wt
CAD7 3.9 (3–5) 49.0 (30–69) 1.9 (1–3) 1.7 (0–4) 64.7 (62–67) wt wt
CAD8 4.0 (3–5) 55.4 (41–71) 1.1 (1–2) 1.1 (1–2) 64.7 (62–66) wt wt
CAD9 5.3 (4–6) 38.0 (23–50) 0.9 (0–1) 0.8 (0–1) 64.0 (60–66) wt wt
CAD10 9.1 (6–13) 19.2 (9–31) 1.3 (1–2) 1.4 (0–3) 65.0 (64–67) wt wt
CAD11 10.3 (5–13) 48.8 (25–70) 1.6 (1–3) 1.6 (1–3) 71.3 (69–73) wt Mut (S)
CAD12 10.8 (7–26) 59.4 (48–67) 1.3 (1–2) 2.1 (1–4) 63.7 (61–66) wt wt
CAD13 15.8 (11–19) 8.0 (7–11) 5.4 (2–14) 0.4 (0–2) 72.7 (71–75) wt wt
CAD14 19.5 (12–26) 46.6 (32–59) 1.4 (1–2) 4.0 (2–8) 72.7 (70–77) wt wt
CAD15 23.4 (15–30) 52.8 (38–67) 2.6 (2–3) 1.4 (1–2) 68.0 (66–72) wt wt
CAD16 26.8 (8–38) 60.4 (49–73) 1.6 (1–3) 5.3 (3–7) 66.7 (63–69) wt wt
CAD17 26.9 (9–36) 39.6 (15–77) 2.7 (2–3) 1.3 (1–2) 65.3 (64–66) wt wt
CAD18 28.7 (11–37) 57.4 (47–67) 0.9 (0–2) 0.6 (0–3) 62.3 (60–64) wt wt
CAD19 30.0 (11–38) 50.2 (36–71) 1.0 (1–1) 1.0 (0–2) 70.7 (69–74) wt wt
CAD20 30.9 (16–36) 58.2 (30–86) 2.3 (1–4) 1.0 (1–1) 64.3 (61–67) wt wt
CAD21 31.0 (18–38) 24.2 (14–37) 3.9 (2–7) 1.9 (1–2) 73.3 (71–75) wt wt
CAD22 32.5 (16–42) 49.6 (36–59) 1.3 (1–2) 1.3 (1–2) 66.0 (64–68) wt wt
CAD23 32.8 (20–38) 49.8 (29–61) 2.4 (1–5) 2.9 (2–5) 66.7 (64–68) wt wt
CAD24 36.6 (16–45) 63.8 (60–69) 1.1 (1–2) 1.0 (1–1) 68.3 (66–72) Mut (S) wt
CAD25 37.6 (13–43) 69.4 (54–78) 1.3 (1–2) 2.4 (1–4) 69.7 (67–72) wt Mut (S)
CAD26 38.0 (26–57) 52.0 (29–61) 6.9 (4–12) 4.6 (3–8) 69.0 (67–70) wt wt
CAD27 39.2 (32–48) 44.4 (29–57) 1.1 (1–2) 2.1 (0–4) 64.6 (62–66) wt wt
CAD28 45.7 (18–69) 57.8 (27–77) 1.4 (1–3) 3.2 (2–7) 73.7 (72–77) wt wt
CAD29 48.0 (26–60) 29.8 (21–36) 0.9 (0–2) 1.6 (0–3) 66.3 (63–68) wt wt
CAD30 48.2 (38–55) 38.8 (21–49) 1.0 (1–1) 1.3 (1–2) 68.7 (65–71) wt wt
CAD31 54.5 (30–68) 45.8 (22–65) 2.7 (1–7) 1.1 (0–2) 66.3 (62–69) wt wt
CAD32 55.7 (44–63) 71.2 (64–78) 1.1 (1–2) 1.3 (0–4) 60.7 (58–63) wt wt
CAD33 60.6 (34–89) 45.4 (27–63) 8.6 (2–35) 1.6 (1–2) 68.7 (65–71) wt wt
CAD34 64.1 (39–78) 41.0 (25–50) 1.3 (1–2) 2.3 (1–4) 73.3 (70–75) wt Mut (S)
RAD1 1.5 (1–2) 71.4 (60–83) 2.3 (1–4) 2.9 (0–4) 75.3 (73–79) wt n.d.
RAD2 2.0 (1–4) 64.0 (55–72) 14.9 (2–34) 3.4 (0–7) 71.3 (70–72) wt n.d.
RAD3 2.5 (2–3) 66.4 (45–83) 5.9 (1–20) 2.7 (2–4) 67.3 (66–69) wt n.d.
RAD4 6.4 (2–23) 80.0 (63–96) 1.9 (1–4) 1.8 (0–2) 66.3 (65–67) wt n.d.
RAD5 9.6 (5–12) 48.2 (35–58) 7.1 (3–16) 3.2 (2–5) 67.3 (65–69) wt n.d.
RAD6 10.1 (5–27) 46.0 (29–70) 7.1 (3–15) 4.8 (3–7) 74.0 (72–76) wt n.d.
RAD7 11.1 (6–15) 42.2 (23–55) 1.1 (1–2) 3.4 (0–6) 68.3 (66–70) wt n.d.
RAD8 11.6 (7–17) 40.2 (24–49) 2.1 (1–4) 2.1 (0–6) 69.3 (67–71) Mut (S) n.d.
RAD9 21.3 (8–34) 53.2 (22–78) 1.3 (1–3) 3.4 (2–5) 67.7 (65–69) wt n.d.
RAD10 24.9 (17–31) 26.4 (14–46) 5.9 (1–11) 1.5 (0–3) 73.0 (71–75) wt n.d.
RAD11 26.8 (10–47) 41.6 (32–50) 1.1 (1–2) 3.1 (1–6) 71.7 (70–73) wt n.d.
RAD12 32.6 (20–43) 69.8 (63–76) 2.3 (1–5) 1.4 (1–2) 67.7 (65–71) wt n.d.
RAD13 33.9 (16–41) 58.2 (49–68) 1.6 (1–3) 2.0 (1–3) 70.0 (67–72) Mut (S) n.d.
Promoter Methylation in PHPT
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between high APC methylation density and presence of an MEN1
mutation (Figure 3). However, no association was observed between
RASSF1A methylation levels and MEN1 genotype (Table 2).
Furthermore, there was no correlation between APC or RASSF1A
promoter methylation densities and HRPT2 genotype (Table 2).
Case
APC
methylation {
RASSF1A
methylation {
p16
INK4A
methylation {
RAR-b
methylation {
LINE-1
methylation { Genotypes*
no. mean % (range) % mean % (range) % mean % (range) % mean % (range) % mean % (range) % MEN1 HRPT2
RAD14 36.4 (23–46) 53.6 (46–62) 2.0 (1–5) 2.0 (1–4) 68.0 (65–71) Mut (S) n.d.
RAD15 38.6 (23–47) 56.4 (48–63) 0.9 (0–1) 0.9 (0–2) 67.7 (65–69) Mut (S) n.d.
RAD16 43.3 (17–53) 53.4 (36–71) 1.0 (1–1) 1.9 (0–3) 69.0 (66–72) wt n.d.
RAD17 58.0 (46–68) 64.4 (56–78) 1.3 (1–2) 4.8 (0–7) 68.7 (66–71) wt n.d.
RAD18 65.1 (50–78) 72.4 (56–91) 0.7 (0–1) 1.5 (0–8) 67.0 (64–70) Mut (S) n.d.
RAD19 65.9 (55–73) 63.0 (42–74) 1.9 (1–2) 2.8 (0–5) 63.7 (62–66) Mut (S) n.d.
H1 2.3 (1–5) 16.2 (13–19) 1.4 (1–2) 4.1 (2–7) 78.3 (75–83) n.d. Mut (G)
H2 77.5 (30–89) 52.8 (32–62) 1.9 (1–3) 2.6 (1–4) 75.7 (73–78) n.d. Mut (G)
SHPT
SHPT1 2.5 (2–3) 30.2 (16–54) 3.0 (1–5) 1.6 (0–4) 71.3 (69–76) n.d. n.d.
Normal controls
Normal PT1 4.0 (2–7) 5.2 (4–6) 2.9 (1–5) 2.1 (1–4) 60.7 (56–68) n.d. n.d.
Normal PT2 2.2 (1–5) 1.6 (1–2) 3.1 (1–7) 2.2 (1–4) 59.7 (55–67) n.d. n.d.
Normal PT3 3.3 (2–4) 3.0 (3–3) 2.1 (1–3) 2.6 (2–4) 72.3 (68–77) n.d. n.d.
Leukocyte RAD2 2.3 (1–4) 2.8 (2–3) 1.0 (1–1) 3.5 (2–6) 78.0 (75–80) n.d. n.d.
Thymus H1 2.4 (1–5) 3.8 (3–5) 1.6 (1–3) 6.8 (5–9) 77.3 (75–80) n.d. n.d.
{ = Mean CpG methylation density in % (X% CpG1+Y% CpG2)n/n, range within parenthesis.
n.d: not determined; wt = wild-type, Mut (S/G) = somatic/germline mutation.
* Genotypes according to previous publications [3,43–44].
doi:10.1371/journal.pone.0009472.t001
Table 1. Cont.
Figure 2. Global and regional hypermethylation in parathyroid tumours. Individual value plot illustrating the mean densities of CpG
methylation of the APC, RASSF1A, p16
INK4A, RAR-b and LINE-1 promoters for the 55 parathyroid tumours (T) and 3 normal parathyroid controls (N). The
Y axis represents the mean density of methylation calculated as an average of the individual CpG residues assayed.
doi:10.1371/journal.pone.0009472.g002
Promoter Methylation in PHPT
PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9472APC and RASSF1A mRNA Expression Analyses by qRT-
PCR
For APC, we assessed both total levels of APC mRNA and an
APC 1B specific transcript regulated by the APC promoter 1B. No
TaqMan Gene Expression Assay exists exclusively for the APC 1A
transcript. For the total levels of APC mRNA, all 16 parathyroid
adenomas available for qRT-PCR exhibited greater relative
expression levels compared to the normal parathyroid mean,
ranging from 1.3–9 (normal parathyroid mean =1) and a mean
relative expression of 4.5. For the APC 1B transcript, all tumours
displayed greater relative expression levels compared to the
normal parathyroid mean ranging from 2–20 (normal parathyroid
mean =1) and a mean relative expression of 8.7 (Figure 4). For
RASSF1A, all 16 adenomas investigated have been shown to
exhibit RASSF1A hypermethylation ranging from 37.2–71.2%.
Using qRT-PCR, all tumours were found to exhibit lower relative
RASSF1A mRNA expression levels compared to the normal
parathyroid mean value, ranging from 0.05–0,8 (normal parathy-
roid mean =1). The mean relative expression was 0.26, suggesting
that parathyroid adenomas display a noteworthy reduction in
RASSF1A expression compared to normal parathyroid (Figure 4).
Discussion
In this study we demonstrate frequent hypermethylation of the
APC and RASSF1A tumour suppressor genes in the majority of
parathyroid adenomas. RASSF1A promoter hypermethylation led
to diminished RASSF1A mRNA levels in parathyroid adenomas as
compared to normal parathyroid tissues, whereas APC gene
expression is retained through augmented expression of APC 1B
mRNA regulated by APC promoter 1B. In addition, based on
LINE-1 promoter methylation results parathyroid benign tumours
were found to exhibit global methylation levels within range of the
normal parathyroid tissues examined.
APC gene expression is regulated by at least two separate
promoter regions, named 1A and 1B. Hypermethylation of
promoter 1A has been readily demonstrated in various human
tumours; however to our knowledge there is no or little evidence
suggesting epigenetic inactivation of the APC promoter 1B through
hypermethylation [33]. Hence, for this purpose we focused solely
on the APC promoter 1A regarding Pyrosequencing analyses. In
our tumour panel, hypermethylation of the APC promoter 1A was
found in the majority of benign parathyroid tumours, as well as in
one familial HRPT2 related case. These results are supported by
research in colorectal tumorigenesis, where promoter 1A methyl-
ation is regarded as an early event and is readily detected in small
colorectal adenomas [33]. Furthermore, in this study all 16
adenomas analyzed by qRT-PCR displayed augmented APC 1B
mRNA levels as compared to normal parathyroid tissues, strongly
suggesting that the APC promoter 1B is not epigenetically silenced
in these tumours.
Parafibromin, encoded by HRPT2, is a vital part of the hPAF
complex involved in epigenetic modifications for facilitating gene
transcription, and has also been shown to specifically regulate c-
Myc oncogene expression through binding directly to the c-Myc
promoter region [7]. Our results do not point towards a specific
correlation between APC promoter methylation and HRPT2 gene
mutations, suggesting that parafibromin may not play an apparent
role in the regulation of APC promoter 1A methylation. However,
APC promoter 1A methylation displayed a weak but significant
correlation to the tumour suppressor MEN1 genotype, and all
parathyroid tumours with MEN1 mutations in our panel displayed
APC hypermethylation ranging from 11.6–65.9% (Figure 2).
Interestingly, the MEN1 protein product menin has recently been
implicated as an epigenetic modifier of Axin2, a component within
the Wnt pathway as well as an APC-associated protein [8]. Our
study vaguely implies that menin might regulate the levels of APC
promoter methylation at the DNA level in parathyroid cells, since
Table 2. Correlations between hypermethylation levels and
tumour characteristics.
Parameter RASSF1A APC
RASSF1A - 0.301 (p=0.022)
APC 0.301 (p=0.022) -
Gender n.s. n.s.
Age at diagnosis n.s. n.s.
S-Ca 20.417 (p=0.003) n.s.
S-PTH n.s. n.s.
Tumour weight n.s. n.s.
MEN1 mutation n.s. 0.322 (p=0.027)
HRPT2 mutation n.s. n.s.
n.s: not significant.
doi:10.1371/journal.pone.0009472.t002
Table 3. Summary of the parathyroid tumour study group.
Parameter
Number of samples/patients 55
Sex
female 33
male 22
Age at diagnosis
median (range) years 62 (16–86)
Familial disease
sporadic 52
HPT-JT 2
FIHP 1
Histopathology
adenoma 53
atypical adenoma 2
S-Ca
median (range) mmol/L 2.85 (2.60–4.00)
S-PTH
median (range) ng/L 121 (36–711)
Tumor size
median (range) gram 1.24 (0.20–11.18)
MEN1 sequence
mutated 7
wild-type 46
n.a. 2
HRPT2 sequence
mutated 5
wild-type 31
n.a. 19
n.a: not available.
doi:10.1371/journal.pone.0009472.t003
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methylation than wild-type cases. Further molecular studies are
needed to investigate the potential role of menin as a DNA
regulator of APC promoter methylation status in addition to its
known role as an Axin2 regulator through histone methylation.
The RASSF1A promoter was found to be hypermethylated in
nearly all parathyroid adenomas examined and RASSF1A gene
expression levels were considerably reduced in adenomas
compared to normal parathyroid tissue. These data strongly
support the involvement of this tumour suppressor gene in
parathyroid tumorigenesis. In unrelated tumour tissues, RASSF1A
promoter methylation has been shown to greatly diminish the
levels of RASSF1A mRNA transcription, and subsequent usage of
demethylating agents such as 5-Aza-CdR reconstitutes the
RASSF1A transcription levels [34]. The role of RASSF1A as a
cyclin D1 posttranslational modifier motivated us to correlate our
methylation data to previous cyclin D1 expression results for the
parathyroid cystic adenomas published elsewhere [35]. However,
no statistical correlation between increased RASSF1A promoter
methylation density and over-expressed cyclin D1 levels were seen
(data not shown), suggesting that RASSF1A hypermethylation at
least in part might contribute to excessive parathyroid tumour
growth by other means than cyclin D1 accumulation, for example
through its role as a regulator of apoptosis and mitotic arrest [19].
Regarding APC, we demonstrate three cases of normal
parathyroid tissue (Normal PT1-3) as well as a case of secondary
hyperparathyroidism with hyperplasia (case SHPT1) displaying
virtually no CpG promoter methylation, suggesting that methyl-
ation of this locus might be conserved to true tumorous lesions of
the parathyroids, such as adenomas and carcinomas. Moreover,
studies have shown that normal adrenal as well as normal colonic
mucosa in general shows APC promoter 1A methylation levels
below 5%, as compared to the higher levels observed in the
corresponding tumours [20,32]. Also, the vast majority of cases of
normal breast and lung tissue display an un-methylated APC
promoter 1A as compared to the corresponding tumours [15,36];
consequently these are examples which illustrate the tumour-
specific phenotype for APC promoter 1A methylation in some
tissue types.
For RASSF1A, the three normal parathyroid samples were
endowed with virtually no methylation (2.0%, 3.6% and 3.0%
respectively) whereas case SHPT1 was endowed with a methyl-
ation density of approximately 30%, suggesting that RASSF1A
methylation also can be found in parathyroid tissue with an
disproportionate growth pattern, albeit not a tumour per
definition. Interestingly, cyclin D1 over-expression is also found
in a fraction of cases with secondary hyperparathyroidism,
suggesting that a subset of these lesions are propelled in parts by
processes similar to those present in parathyroid adenomas and
carcinomas [37]. Hence, the finding of RASSF1A hypermethyla-
tion in case SHPT1 could imply that this process could contribute
to pathological growth in secondary hyperparathyroidism in
addition to adenomas. In other non-neoplastic endocrine tissues
such as the normal adrenal medulla and normal thyroid tissue, the
RASSF1A promoter habitually exhibit low levels (,10%) of
methylation densities with few exceptions [20–21]. In our study,
normal thymus and leukocyte DNA was used as additional
controls and displayed low levels of RASSF1A methylation,
validating the specificity of our findings. Furthermore, a tumour
case in our study displayed virtually no RASSF1A promoter
methylation (CAD13, 8%), suggesting that parathyroid tissue not
routinely exhibit high levels of methylation at this locus.
It is not known whether the hypermethylation of APC promoter
1A bears any pathological consequences to parathyroid growth,
since APC protein expression has been previously demonstrated in
parathyroid adenomas [16,27]. However, a recent study has
shown reduced APC promoter 1A mRNA levels in colorectal
tumours with APC promoter 1A hypermethylation although
Figure 3. APC promoter 1A hypermethylation in parathyroid tumours with a coupling to MEN1 mutations. Boxplot displaying APC
promoter methylation in comparison to MEN1 genotype for all cases where genotype data was available. The endpoints of the boxes represent the
first and third quartiles respectively, and the horizontal line corresponds to the median. High APC promoter methylation density is statistically
correlated to MEN1 mutational status.
doi:10.1371/journal.pone.0009472.g003
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and the authors advocate that even a slight decrease of APC gene
transcription through the epigenetic silencing of promoter 1A
could have an impact on Wnt signalling, although via unknown
mechanisms [33]. Furthermore, another study regarding colorec-
tal cancer found no correlations between APC methylation levels
and APC protein expression [38]. In this study, we found notably
augmented levels of total APC mRNA levels (from promoters 1A
and 1B) as well as APC 1B mRNA in the adenomas investigated by
qRT-PCR, of which 13 out of 16 samples displayed APC promoter
1A hypermethylation (Figure 4). These data imply that APC 1B
mRNA is highly expressed in parathyroid adenomas, suggesting
that the APC promoter 1B is not epigenetically inactivated in these
cases. This presents a credible explanation to the fact that
parathyroid adenomas display retained APC protein expression as
demonstrated in previous publications although possibly endowed
with APC promoter 1A hypermethylation [16,27]. Furthermore,
the finding of elevated levels of total APC mRNA is most likely a
result of elevated levels of APC 1B mRNA expression, and does not
argue directly against the theoretical, specific down-regulation of
the APC 1A mRNA, the latter which is an observed phenomenon
in colon cancer research [33]. In studies of unrelated tumour
tissues, APC promoter 1A methylation is coupled to down-
regulation of APC 1A mRNA, and treatment with demethylating
agents results in re-expression of the specific transcript, demon-
strating the sensible correlation between APC promoter methyla-
tion and APC mRNA transcript levels in vivo [39].
LINE-1 bisulphite Pyrosequencing analysis has been shown to
be an efficient substitute for global methylation assays [31], and
our data thus suggests that parathyroid tumours display compa-
rable methylation levels globally as normal parathyroid cells. This
finding was unexpected, considering the current notion that
human cancers generally exhibit global hypomethylation. In
support of our findings, a current study recently demonstrated
global hypermethylation in patients with myelodysplastic syn-
drome (MDS) as compared to normal controls using LINE-1
Pyrosequencing [40]. The authors furthermore observed note-
worthy clinical improvement among MDS patients when treated
with hypomethylation-inducing agents, suggesting that the global
hypermethylation was of clinical significance in this tumour type.
Hence, these data suggest that not all tumours display relative
hypomethylation globally compared to their corresponding
normal tissues. In addition, we found that male cases displayed
significantly higher levels of LINE-1 methylation than female cases
(Pearson’s correlation 20.466, p,0.001), and cases with higher
age at surgery displayed lower levels of LINE-1 methylation than
younger cases (Pearson’s correlation 0.320, p=0.018). These
observations may suggest an influence of age or gender upon
global levels of methylation in parathyroid tissues.
In summary, this study is the first to identify APC and RASSF1A
promoter hypermethylation in the majority of parathyroid
tumours investigated. The frequently observed hypermethylation
of the RASSF1A promoter and downregulation of RASSF1A
mRNA levels in parathyroid adenomas point toward an
association between the inactivation of this tumour suppressor
gene and parathyroid aberrant growth, whereas APC gene
expression is retained in parathyroid adenomas due to increased
transcription from APC promoter 1B. Moreover, LINE-1 analyses
indicate that parathyroid tumours do not exhibit global hypo-
methylation as compared to normal parathyroid tissues.
Materials and Methods
Ethics Statement
Fifty-five samples of parathyroid adenoma were collected with
informed verbal consent. Informed verbal consent constitutes
standard procedure at the Karolinska University Hospital, and the
consent is subsequently documented in the patient’s medical
journal as according to Swedish Biobank law. The procedure has
been specifically approved by the Karolinska University Hospital
Ethics Committee and by the Karolinska Institute Research Ethics
Committee, and these approvals include collection of normal
parathyroid biopsies as well as normal tissues (including blood and
thymus tissue) whenever motivated from patients undergoing
surgery for primary and secondary hyperparathyroidism.
Patients and Tissue Samples
Fifty-five samples of parathyroid adenoma were collected for the
study (Tables 1 and 3, Table S1). Histopathological classifications
were according to the guidelines of the World Health Organization
(WHO) [41]. Thirty-four cases were parathyroid adenomas with
cystic features (CAD1-34), which have previously been reported in
Figure 4. Interval plots demonstrating relative RASSF1A and
APC gene expression in parathyroid tumours. 16 adenomas were
compared to the normal parathyroid mean regarding (A) RASSF1A and
(B) total APC and APC 1B gene expression. The endpoints of the
intervals represent the 95% confidence interval for the mean, and the
diamond corresponds to the mean value.
doi:10.1371/journal.pone.0009472.g004
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Thirty-three of these cases were sporadic and one single case
(CAD11)wasderived from a 1q linkedFIHPfamily. Inadditionone
case (CAD25)wasclassifiedasanatypicaladenoma.Twoadditional
HRPT2 related adenomas were derived from patients with germ-
line HRPT2 mutations (H1-2). Tumor H1 exhibited atypical
histological findings that are sometimes seen in malignant
parathyroid tumours, but was without definite criteria of malignan-
cy in agreement with the diagnosis atypical adenoma or equivocal
carcinomas as previously applied [42]. Nineteen cases were regular
parathyroid adenomas (RAD1-19) that have been previously
characterized for MEN1 genotype [43–44]. Moreover, a case of
parathyroid hyperplasia due to secondary hyperparathyroidism
(SHPT1) was also included in the study. As non-tumorous normal
controls, three samples of normal parathyroid tissue derived from
surgical biopsies were included together with human leukocyte
DNA from patient RAD2 as well as thymic tissue from patient H1.
Bisulphite Treatment of DNA and Pyrosequencing
Analyses
Sodium bisulphite modification of 500 ng DNA was carried out
with the EZ DNA methylation kit (D5002, Zymo Research
Corporation, CA, USA) following the manufacturer’s protocol.
The subsequent PCR and Pyrosequencing analysis to assess the
level of methylation was carried out essentially as previously
described for 10 CpG sites of the APC promoter 1A [20], 7 CpG
sites of the p16
INK4A promoter [45], 5 CpG sites of the RASSF1A
promoter [46], 10 CpG sites of the RAR-b promoter [20] and 3
CpG sites of the LINE-1 promoter [20]. Primer sequences are
available at the PyroMark Assay Database (Biotage, Sweden) for
all assays with the exception of p16
INK4A, and were designed to
hybridize with CpG-free regions to secure methylation-indepen-
dent amplification. HotStar Taq polymerase was used to amplify
1 ml of bisulphite–treated DNA. PCR conditions were 95uC
15 min followed by 45 cycles of: 95uC2 0s ,5 0 uC( RAR-b and
LINE-1)o r5 5 uC( APC, RASSF1A, p16
INK4A)2 0 s ,7 2 uC2 0 s ,
followed by 72uC 5 min and finally 4u C. All samples and blank
controls for each reaction (PCR water control and additional non-
PCR water control) were then analyzed using Pyrosequencing
analysis and the PyroMark Q24 system (Biotage). Subsequent
quantification of methylation density was done using the Pyro-
Mark Q24 software. Cases of bisulphite-treated normal leukocyte
and thymic DNA were assessed as additional negative controls.
Subsets of cases were re-analyzed with repeated PCR and
Pyrosequencing reactions to test the validity of the initial
Pyrosequencing findings for all promoter regions included, with
similar end results (data not shown). Subsets of cases (including
both tumour and normal parathyroid samples) were also
repeatedly bisulphite treated and subsequently analyzed using
PCR and Pyrosequencing, with analogous results (data not shown).
We chose to define hypermethylation as an average CpG
residue methylation above 10% for APC, RASSF1A, p16
INK4A and
RAR-beta since the normal parathyroid mean as well as other
normal tissues in this study were below this value.
RNA Isolation, cDNA Synthesis and Quantitative RT-PCR
(qRT-PCR)
TotalRNAwas availablefor16ofthe parathyroidadenomasand
two of the normal parathyroid glands (normal PT1-2). All samples
were extracted using the TRIzol Reagent (Invitrogen, CA, USA)
and subsequently purified with the RNeasy kit (Qiagen, CA, USA).
The RNA quality was verified using the NanoDrop ND-1000
(Thermo Scientific, DE, USA) for confirmation of acceptable 260/
280 nm absorbance ratio as well as determining the sample
concentrations. In addition, all RNA samples were analyzed in
agarose gels where the integrity of the 28S and 18S bands was
verified. Subsequent cDNA synthesis was performed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
CA, USA) following the company protocol. Subsequent assessment
of APC and RASSF1A mRNA levels was carried out by quantitative
RT-PCR (qRT-PCR) using the TaqMan Gene Expression Assay
Technique and the 7900HT Fast Real-Time PCR System (Applied
Biosystems, CA, USA). For APC, two assays were included;
Hs00181051_m1 which covers total levels of APC mRNA (covering
three transcript variants, one regulated from promoter 1A and two
from 1B) and Hs01568282_m1 which covers the specific APC 1B
transcript regulated by promoter 1B. There is no assay available
exclusively for the analysis of the APC 1A transcript regulated by the
APC promoter 1A using the TaqMan Gene Expression Assay
technique. The RPLP0 (ribosomal protein, large, P0), also known as
36B4,hasbeenused inpreviouspublicationsbytheauthors and was
selected as a housekeeping reference known to demonstrate little
variationinparathyroidtissues(Hs99999902_m1)[35].FortheAPC
promoter 1A, 13/16 adenomas available for qRT-PCR displayed
hypermethylation ranging from 10.3–64.1%. For RASSF1A,a l l1 6
adenomas analyzed demonstrated RASSF1A promoter hypermethy-
lation ranging from 37.2–71.2%. The two normal parathyroid
tissues analyzed were devoid of hypermethylation covering both the
RASSF1A and APC promoters.
A standard curve was established for relative quantification
using cDNA from tumour case CAD20, and the qRT-PCR was
carried out in 25 ml reactions with 12.5 ml TaqMan Gene
Expression Master Mix, 8.5 ml RNase free H2O, 1 ml TaqMan
Gene Expression Assay and 3 ml cDNA. The thermocycling
conditions were 50uC for 2 min, 95uC for 10 min followed by 40
cycles of 95uC for 15 sec and 60uC for 1 min. Two non-template
controls were assessed as negative controls for each experiment,
and all experiments were carried out in double. After quantifica-
tion relative to the standard curve, all samples were normalized to
their corresponding RPLP0 value and thereafter the normal
parathyroid mean for each assay.
Statistical Analyses
Possible correlations between methylation density in the
different promoters assayed as well as between individual
promoters and clinical/genetic characteristics were evaluated
using the Minitab 15 statistical software (Minitab Inc, PA, USA).
Correlations were appraised by Pearson’s correlation and
differences between groups were verified using Fisher’s exact test.
P-values ,0.05 were considered as statistically significant.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0009472.s001 (0.03 MB
XLS)
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